Table 4 Clinical management of FN based on expert opinion
Drug name | Patients treated among those developing FN (%)a | Total daily dose (mg) | Average duration (days) |
|---|---|---|---|
Piperacillin + tazobactam | 34% | 16 000 | 6.1 |
Amikacin | 26% | 1 000 to 1 500 | 4.1 |
Ceftazidime | 18% | 2 625 to 4 000 | 5 |
Amoxycillin + clavulanic acid | 17% | 6 000 | 5.4 |
Cefepime | 14% | 6 000 to 16 000 | 5.8 |
Filgrastim | 13% | 0.3 | 4.5 |
Fluconazole | 8% | 200 to 400 | 6.5 |
Ciprofloxacin | 7% | 0.3 | 5.5 |
Procedure name | Patients treated among those developing FN (%)* | Average frequency of procedure | |
Chest X-ray | 80% | 1.2 | |
Microbiological tests | 78% | 2.4 | |
Abdominal echography | 7% | 1.0 | |
Hospitalization by usage of PP/SP | Patients hospitalized among those developing FN (%) | Average [range] LOS (days) | |
No G-CSF prophylaxis | 48% | 4.2 [3-7] | |
PP | 19% | 1.5 [1-2] | |
SP | 20% | 3.3 [3-7] | |